{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T10:12:11Z","timestamp":1775470331451,"version":"3.50.1"},"reference-count":76,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dermatol Surg","DS"],"published-print":{"date-parts":[[2019,1]]},"abstract":"<jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Locally advanced and metastatic nonmelanoma skin cancer (NMSC) not amenable to surgical resection requires a different approach to therapy.<\/jats:p><\/jats:sec><jats:sec><jats:title>OBJECTIVE<\/jats:title><jats:p>To review the efficacy and adverse effects of emerging treatment options for locally advanced and metastatic NMSC.<\/jats:p><\/jats:sec><jats:sec><jats:title>MATERIALS AND METHODS<\/jats:title><jats:p>A comprehensive search on PubMed was conducted to identify relevant literature investigating the role of program cell death 1 (PD-1) inhibitor, cytotoxic T-lymphocyte\u2013associated antigen 4 (CTLA-4) inhibitor, epidermal growth factor receptor (EGFR) inhibitor, and Hedgehog pathway inhibitors in the treatment of NMSC.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>PD-1 inhibitor and CTLA-4 inhibitor have shown promising efficacy with tolerable side-effect profiles in the treatment of NMSC, although the number of cases reported is limited. Currently, 3 larger-scale clinical trials are investigating PD-1 inhibitor therapy for NMSC. Similarly, EGFR inhibitor demonstrated marginal success in unresectable cutaneous squamous cell carcinomas. Hedgehog pathway inhibitors were approved by the US FDA for treatment of locally advanced and metastatic basal cell carcinomas and have shown favorable efficacy. Common adverse effects included muscle spasm, alopecia, and dysgeusia.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSION<\/jats:title><jats:p>Systemic therapies including PD-1 inhibitors and CTLA-4 inhibitors have demonstrated early promising results for difficult-to-treat NMSC. Future studies are necessary to optimize treatment outcome.<\/jats:p><\/jats:sec>","DOI":"10.1097\/dss.0000000000001601","type":"journal-article","created":{"date-parts":[[2018,7,19]],"date-time":"2018-07-19T12:37:13Z","timestamp":1532003833000},"page":"1-16","source":"Crossref","is-referenced-by-count":21,"title":["Emerging Nonsurgical Therapies for Locally Advanced and Metastatic Nonmelanoma Skin Cancer"],"prefix":"10.1097","volume":"45","author":[{"given":"Leon","family":"Chen","sequence":"first","affiliation":[{"name":"Department of Dermatology, The University of Texas McGovern Medical School at Houston, Houston, Texas;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander B.","family":"Aria","sequence":"additional","affiliation":[{"name":"The University of Texas McGovern Medical School at Houston, Houston, Texas;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sirunya","family":"Silapunt","sequence":"additional","affiliation":[{"name":"Department of Dermatology, The University of Texas McGovern Medical School at Houston, Houston, Texas;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael R.","family":"Migden","sequence":"additional","affiliation":[{"name":"Departments of Dermatology and Head and Neck Surgery, The University of Texas MD Anderson Cancer Center, Houston, Texas"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230814","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1001\/jamadermatol.2015.1187","article-title":"Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the US population, 2012","volume":"6360","author":"Rogers","year":"2015","journal-title":"JAMA Dermatol"},{"key":"R2-20230814","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/0190-9622(91)70108-E","article-title":"Metastatic basal cell carcinoma: report of twelve cases with a review of the literature","volume":"24","author":"Lo","year":"1991","journal-title":"J Am Acad Dermatol"},{"key":"R3-20230814","doi-asserted-by":"crossref","first-page":"213","DOI":"10.5021\/ad.2011.23.2.213","article-title":"Pulmonary metastasis of Basal cell carcinoma","volume":"23","author":"Seo","year":"2011","journal-title":"Ann Dermatol"},{"key":"R4-20230814","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1097\/DSS.0000000000000478","article-title":"Consensus for nonmelanoma skin cancer treatment, Part II: squamous cell carcinoma, including a cost analysis of treatment methods","volume":"41","author":"Kauvar","year":"2015","journal-title":"Dermatol Surg"},{"key":"R5-20230814","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1056\/NEJMoa1113713","article-title":"Efficacy and safety of vismodegib in advanced basal-cell carcinoma","volume":"366","author":"Sekulic","year":"2012","journal-title":"N Engl J Med"},{"key":"R6-20230814","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1016\/S1470-2045(15)70100-2","article-title":"Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial","volume":"16","author":"Migden","year":"2015","journal-title":"Lancet Oncol"},{"key":"R7-20230814","first-page":"1","article-title":"Systemic therapy in advanced cutaneous squamous cell carcinoma (CSCC): the Roswell park experience and a review of the literature","volume":"0","author":"Jarkowski","year":"2014","journal-title":"Am J Clin Oncol"},{"key":"R8-20230814","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1158\/1055-9965.EPI-14-0654","article-title":"Programmed cell death 1 (PD-1) and its ligand (PD-L1) in common cancers and their correlation with molecular cancer type","volume":"23","author":"Gatalica","year":"2014","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"R9-20230814","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1136\/bmj.1.5022.779","article-title":"Cancer\u2014a biological approach. I. The processes of control","volume":"1","author":"Burnet","year":"1957","journal-title":"Br Med J"},{"key":"R10-20230814","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4103\/0974-2077.94323","article-title":"Nonmelanoma skin cancer","volume":"5","author":"Samarasinghe","year":"2012","journal-title":"J Cutan Aesthet Surg"},{"key":"R11-20230814","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1056\/NEJMra022137","article-title":"Skin cancers after organ transplantation","volume":"348","author":"Euvrard","year":"2003","journal-title":"N Engl J Med"},{"key":"R12-20230814","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1067\/mjd.2002.125579","article-title":"Skin cancer in organ transplant recipients: epidemiology, pathogenesis, and management","volume":"47","author":"Berg","year":"2002","journal-title":"J Am Acad Dermatol"},{"key":"R13-20230814","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1001\/archderm.1986.01660230080015","article-title":"Cutaneous malignant neoplasms in patients with renal transplants","volume":"122","author":"Gupta","year":"1986","journal-title":"Arch Dermatol"},{"key":"R14-20230814","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1002\/1097-0142(19870201)59:3<540::AID-CNCR2820590330>3.0.CO;2-U","article-title":"Squamous cell carcinoma of head and neck in patients with well-differentiated lymphocytic lymphoma","volume":"59","author":"Perez-Reyes","year":"1987","journal-title":"Cancer"},{"key":"R15-20230814","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/0190-9622(92)70144-5","article-title":"Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection","volume":"26","author":"Rowe","year":"1992","journal-title":"J Am Acad Dermatol"},{"key":"R16-20230814","first-page":"571","article-title":"Skin cancer in patients with chronic lymphocytic leukemia and non-Hodgkin lymphoma","volume":"10","author":"Onajin","year":"2012","journal-title":"Clin Adv Hematol Oncol"},{"key":"R17-20230814","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1002\/cncr.10178","article-title":"Immunotherapy for nonmelanoma skin cancer: does it have a future?","volume":"94","author":"Urosevic","year":"2002","journal-title":"Cancer"},{"key":"R18-20230814","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1751-1097.2007.00231.x","article-title":"Molecular and cellular mechanisms of photocarcinogenesis","volume":"84","author":"Beissert","year":"2008","journal-title":"Photochem Photobiol"},{"key":"R19-20230814","first-page":"6102","article-title":"Ultraviolet radiation and immunology: something new under the sun-presidential address","volume":"54","author":"Kripke","year":"1994","journal-title":"Cancer Res"},{"key":"R20-20230814","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1002\/(SICI)1096-9896(199902)187:3<351::AID-PATH227>3.0.CO;2-6","article-title":"Interferon-gamma-induced ICAM-1 and CD40 expression, complete lack of HLA-DR and CD80 (B7.1), and inconsistent HLA-ABC expression in basal cell carcinoma: a possible role for interleukin-10?","volume":"187","author":"Kooy","year":"1999","journal-title":"J Pathol"},{"key":"R21-20230814","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1111\/j.1751-1097.2007.00275.x","article-title":"Early events in UV carcinogenesis\u2013DNA damage, target cells and mutant p53 foci","volume":"84","author":"de Gruijl","year":"2008","journal-title":"Photochem Photobiol"},{"key":"R22-20230814","doi-asserted-by":"crossref","first-page":"95","DOI":"10.4251\/wjgo.v7.i8.95","article-title":"Anti program death-1\/anti program death-ligand 1 in digestive cancers","volume":"7","author":"de Guillebon","year":"2015","journal-title":"World J Gastrointest Oncol"},{"key":"R23-20230814","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic basis for clinical response to CTLA-4 blockade in melanoma","volume":"371","author":"Snyder","year":"2014","journal-title":"N Engl J Med"},{"key":"R24-20230814","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1158\/2159-8290.CD-11-0028","article-title":"Temporal dissection of tumorigenesis in primary cancers","volume":"1","author":"Durinck","year":"2011","journal-title":"Cancer Discov"},{"key":"R25-20230814","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1038\/jid.2014.154","article-title":"NOTCH1 mutations occur early during cutaneous squamous cell carcinogenesis","volume":"134","author":"South","year":"2014","journal-title":"J Invest Dermatol"},{"key":"R26-20230814","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1001\/jamadermatol.2016.5118","article-title":"Expression of programmed cell death ligand in cutaneous squamous cell carcinoma and treatment of locally advanced disease with pembrolizumab","volume":"153","author":"Stevenson","year":"2017","journal-title":"JAMA Dermatol"},{"key":"R27-20230814","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40425-017-0228-3","article-title":"Basal cell carcinoma: PD-L1\/PD-1 checkpoint expression and tumor regression after PD-1 blockade","volume":"5","author":"Lipson","year":"2017","journal-title":"J Immunother Cancer"},{"key":"R28-20230814","doi-asserted-by":"crossref","DOI":"10.1038\/npjgenmed.2016.37","article-title":"Metastatic basal cell carcinoma with amplification of PD-L1: exceptional response to anti-PD1 therapy","author":"Ikeda","year":"2016","journal-title":"NPJ Genom Med"},{"key":"R29-20230814","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/s40425-016-0176-3","article-title":"Responses of metastatic basal cell and cutaneous squamous cell carcinomas to anti-PD1 monoclonal antibody REGN2810","volume":"4","author":"Falchook","year":"2016","journal-title":"J Immunother Cancer"},{"key":"R30-20230814","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1111\/bjd.14664","article-title":"Anti-programmed cell death-1 therapy in nonmelanoma skin cancer","volume":"176","author":"Winkler","year":"2017","journal-title":"Br J Dermatol"},{"key":"R31-20230814","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1111\/bjd.14642","article-title":"Rescue therapy with anti-programmed cell death protein 1 inhibitors (PD-1) of advanced cutaneous squamous cell carcinoma and basosquamous carcinoma: preliminary experience in 5 cases","volume":"175","author":"Borradori","year":"2016","journal-title":"Br J Dermatol"},{"key":"R32-20230814","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMc1509268","article-title":"Tumor regression and allograft rejection after administration of anti-PD-1","volume":"374","author":"Lipson","year":"2016","journal-title":"N Engl J Med"},{"key":"R33-20230814","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1001\/jamadermatol.2015.2705","article-title":"A case report of unresectable cutaneous squamous cell carcinoma responsive to pembrolizumab, a programmed cell death protein 1 inhibitor","volume":"152","author":"Chang","year":"2016","journal-title":"JAMA Dermatol"},{"key":"R34-20230814","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am J Clin Oncol"},{"key":"R35-20230814","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Ishida","year":"1992","journal-title":"EMBO J"},{"key":"R36-20230814","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s00262-017-1954-6","article-title":"PD-1 and PD-L1 antibodies in cancer: current status and future directions","volume":"66","author":"Balar","year":"2017","journal-title":"Cancer Immunol Immunother"},{"key":"R37-20230814","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma","volume":"372","author":"Ansell","year":"2015","journal-title":"N Engl J Med"},{"key":"R38-20230814","first-page":"1","article-title":"FDA approval summary: nivolumab for the treatment of metastatic non-small cell lung cancer with progression on or after platinum-based chemotherapy","volume":"21","author":"Kazandjian","year":"2016","journal-title":"Oncologist"},{"key":"R39-20230814","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/S1470-2045(17)30065-7","article-title":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial","volume":"18","author":"Sharma","year":"2017","journal-title":"Lancet Oncol"},{"key":"R40-20230814","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s11864-017-0458-0","article-title":"Checkpoint inhibitors for the treatment of renal cell carcinoma","volume":"18","author":"Ghatalia","year":"2017","journal-title":"Curr Treat Options Oncol"},{"key":"R41-20230814","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"R42-20230814","doi-asserted-by":"crossref","first-page":"4311","DOI":"10.1200\/JCO.2013.51.4802","article-title":"Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma","volume":"31","author":"Weber","year":"2013","journal-title":"J Clin Oncol"},{"key":"R43-20230814","doi-asserted-by":"crossref","first-page":"6012","DOI":"10.1200\/JCO.2016.34.15_suppl.6012","article-title":"Efficacy and safety of pembrolizumab in recurrent\/metastatic head and neck squamous cell carcinoma (R\/M HNSCC): pooled analyses after long-term follow-up in KEYNOTE-012","volume":"34","author":"Ranee","year":"2016","journal-title":"J Clin Oncol"},{"key":"R44-20230814","doi-asserted-by":"crossref","first-page":"256","DOI":"10.4161\/mabs.2.3.11641","article-title":"The immunogenicity of humanized and fully human antibodies: residual immunogenicity resides in the CDR regions","volume":"2","author":"Harding","year":"2010","journal-title":"MAbs"},{"key":"R45-20230814","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1001\/jama.2016.4059","article-title":"Association of pembrolizumab with tumor response and survival among patients with advanced melanoma","volume":"315","author":"Ribas","year":"2016","journal-title":"JAMA"},{"key":"R46-20230814","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N Engl J Med"},{"key":"R47-20230814","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s13073-016-0365-1","article-title":"Acquired resistance to anti-PD1 therapy: checkmate to checkpoint blockade?","volume":"8","author":"O'Donnell","year":"2016","journal-title":"Genome Med"},{"key":"R48-20230814","first-page":"1","article-title":"Durable response of metastatic squamous cell carcinoma of the skin to ipilimumab immunotherapy","volume":"0","author":"Day","year":"2016","journal-title":"J Immunother"},{"key":"R49-20230814","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jdcr.2015.11.007","article-title":"Incidental regression of an advanced basal cell carcinoma after ipilimumab exposure for metastatic melanoma","volume":"2","author":"Mohan","year":"2016","journal-title":"JAAD Case Rep"},{"key":"R50-20230814","first-page":"505","article-title":"The EGF receptor\u2014an essential regulator of multiple epidermal functions","volume":"10","author":"Jost","year":"2000","journal-title":"Eur J Dermatol"},{"key":"R51-20230814","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1242\/jcs.110.2.113","article-title":"EGF-R dependent regulation of keratinocyte survival","volume":"110","author":"Rodeck","year":"1997","journal-title":"J Cel Sci"},{"key":"R52-20230814","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1002\/hed.21419","article-title":"Dual inhibition of epidermal growth factor receptor and insulin-like growth factor receptor I reduces angiogenesis and tumor growth in cutaneous squamous cell carcinoma","volume":"33","author":"Galer","year":"2011","journal-title":"Head Neck"},{"key":"R53-20230814","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.radonc.2005.06.022","article-title":"Inhibition of radiation-induced EGFR nuclear import by C225 (Cetuximab) suppresses DNA-PK activity","volume":"76","author":"Dittmann","year":"2005","journal-title":"Radiother Oncol"},{"key":"R54-20230814","doi-asserted-by":"crossref","first-page":"3419","DOI":"10.1200\/JCO.2010.34.1735","article-title":"Phase II study of cetuximab as first-line single-drug therapy in patients with unresectable squamous cell carcinoma of the skin","volume":"29","author":"Maubec","year":"2011","journal-title":"J Clin Oncol"},{"key":"R55-20230814","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1001\/jamadermatol.2017.0270","article-title":"Association of oncogenic mutations in patients with advanced cutaneous squamous cell carcinomas treated with cetuximab","volume":"153","author":"Picard","year":"2017","journal-title":"JAMA Dermatol"},{"key":"R56-20230814","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1111\/j.1600-6143.2009.02997.x","article-title":"Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: reduced rate of (pre-)malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial","volume":"10","author":"Salgo","year":"2010","journal-title":"Am J Transpl"},{"key":"R57-20230814","doi-asserted-by":"crossref","first-page":"4335","DOI":"10.7314\/APJCP.2012.13.9.4335","article-title":"Sirolimus and non-melanoma skin cancer prevention after kidney transplantation: a meta-analysis","volume":"13","author":"Gu","year":"2012","journal-title":"Asian Pac J Cancer Prev"},{"key":"R58-20230814","doi-asserted-by":"crossref","first-page":"S131","DOI":"10.1016\/S0959-8049(16)32990-2","article-title":"Phase 1b\/2 trial of taladegib (LY2940680), a Hh\/Smo inhibitor, in combination with carboplatin and etoposide followed by taladegib maintenance in extensive-stage small-cell lung cancer","volume":"69","author":"Schaefer","year":"2016","journal-title":"Eur J Cancer"},{"key":"R59-20230814","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/384129a0","article-title":"The tumour-suppressor gene patched encodes a candidate receptor for Sonic Hedgehog","volume":"384","author":"Stone","year":"1996","journal-title":"Nature"},{"key":"R60-20230814","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/34201","article-title":"Activating Smoothened mutations in sporadic basal-cell carcinoma","volume":"391","author":"Xie","year":"1998","journal-title":"Nature"},{"key":"R61-20230814","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1046\/j.1523-1747.1998.00222.x","article-title":"Identification of mutations in the human PATCHED gene in sporadic basal cell carcinomas and in patients with the basal cell nevus syndrome","volume":"110","author":"Aszterbaum","year":"1998","journal-title":"J Invest Dermatol"},{"key":"R62-20230814","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1016\/j.jaad.2015.03.021","article-title":"Pivotal ERIVANCE basal cell carcinoma (BCC) study: 12-month update of efficacy and safety of vismodegib in advanced BCC","volume":"72","author":"Sekulic","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"R63-20230814","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.jaad.2016.02.1226","article-title":"The 12-month analysis from Basal Cell Carcinoma Outcomes with LDE225 Treatment (BOLT): a phase II, randomized, double-blind study of sonidegib in patients with advanced basal cell carcinoma","volume":"75","author":"Dummer","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"R64-20230814","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.2217\/fon-2016-0118","article-title":"Sonidegib for the treatment of advanced basal cell carcinoma: a comprehensive review of sonidegib and the BOLT trial with 12-month update","volume":"12","author":"Chen","year":"2016","journal-title":"Futur Oncol"},{"key":"R65-20230814","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ccell.2015.02.001","article-title":"Genomic analysis of smoothened inhibitor resistance in basal cell carcinoma","volume":"27","author":"Sharpe","year":"2015","journal-title":"Cancer Cell"},{"key":"R66-20230814","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"key":"R67-20230814","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1056\/NEJMoa1302369","article-title":"Nivolumab plus ipilimumab in advanced melanoma","volume":"369","author":"Wolchok","year":"2013","journal-title":"N Engl J Med"},{"key":"R68-20230814","first-page":"48","article-title":"Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL)","volume":"10","author":"Ribas","year":"2014","journal-title":"J Clin Oncol"},{"key":"R69-20230814","first-page":"39","article-title":"Phase 3, randomized trial (CheckMate 057) of nivolumab (NIVO) vs. Docetaxel (DOC) in advanced non-squamous (non- SQ) non-small cell lung cancer (NSCLC)-subgroup analyses and patient reported outcomes (PROs)","volume":"27","author":"Horn","year":"2016","journal-title":"Oncol Res Treat"},{"key":"R70-20230814","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1056\/NEJMoa1504627","article-title":"Nivolumab versus docetaxel in advanced squamous-cell non\u2013small-cell lung cancer","volume":"373","author":"Brahmer","year":"2015","journal-title":"N Engl J Med"},{"key":"R71-20230814","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1016\/S1470-2045(15)00307-1","article-title":"PD-L1 expression as a potential predictive biomarker","volume":"16","author":"Fusi","year":"2015","journal-title":"Lancet Oncol"},{"key":"R72-20230814","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1111\/cup.12728","article-title":"PD-L1 expression in cutaneous squamous cell carcinoma correlates with risk of metastasis","volume":"43","author":"Slater","year":"2016","journal-title":"J Cutan Pathol"},{"key":"R73-20230814","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40364-017-0093-8","article-title":"Utility of PD-L1 immunohistochemistry assays for predicting PD-1\/PD-L1 inhibitor response","volume":"5","author":"Diggs","year":"2017","journal-title":"Biomark Res"},{"key":"R74-20230814","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.intimp.2017.03.015","article-title":"Primary and acquired resistance to PD-1\/PD-L1 blockade in cancer treatment","volume":"46","author":"Wang","year":"2017","journal-title":"Int Immunopharmacol"},{"key":"R75-20230814","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3389\/fonc.2012.00095","article-title":"Role of T lymphocytes in tumor response to radiotherapy","volume":"2","author":"Demaria","year":"2012","journal-title":"Front Oncol"},{"key":"R76-20230814","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1517\/14728214.13.2.295","article-title":"Cancer vaccines: on the threshold of success","volume":"13","author":"Emens","year":"2008","journal-title":"Expert Opin Emerg Drugs"}],"container-title":["Dermatologic Surgery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00042728-201901000-00001","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,8]],"date-time":"2024-07-08T11:35:26Z","timestamp":1720438526000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00042728-201901000-00001"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":76,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/dss.0000000000001601","relation":{},"ISSN":["1076-0512","1524-4725"],"issn-type":[{"value":"1076-0512","type":"print"},{"value":"1524-4725","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1]]}}}